REG - Beximco Pharmaceut - World's first generic version of Pfizer’s Paxlovid

Beximco PharmaceuticalsAnnouncement

30/12/2021 10:40

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211230:nRSd0572Xa&default-theme=true

RNS Number : 0572X  Beximco Pharmaceuticals Ltd  30 December 2021

 

30 December 2021

 

BEXIMCO PHARMACEUTICALS LTD.

 

Beximco Pharma introduces world's first generic version of Pfizer's Paxlovid, the first US FDA approved oral therapy for COVID-19 treatment

 

Availability of generic nirmatrelvir and ritonavir will provide affordable
treatment option and increase accessibility as new variants emerge

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"),
the fast-growing manufacturer of generic pharmaceutical products and active
pharmaceutical ingredients, today announces the launch of the world's first
generic version of Pfizer's COVID-19 treatment Paxlovid (nirmatrelvir and
ritonavir tablets, co-packaged for oral use) which was granted emergency use
authorization (EUA) by the US FDA on 22 December 2021. Directorate General of
Drug Administration (DGDA), Bangladesh, has today granted EUA for the oral
antiviral drug to treat mild-to-moderate COVID-19 in adults and children of 12
years and above. This novel antiviral pill showed almost 90% efficacy in
preventing hospitalizations and deaths in high-risk patients, and recent data
from Pfizer suggests the drug retains its effectiveness against the
fast-spreading Omicron variant of the coronavirus. Beximco Pharma will market
this product under the brand name Bexovid, initially in Bangladesh.

 

Nirmatrelvir inhibits a SARS-CoV-2 enzyme to stop the virus from replicating,
and ritonavir slows down nirmatrelvir's breakdown to help it remain in the
body for a longer period at higher concentrations. The treatment is given as
two tablets of nirmatrelvir and one tablet of ritonavir together twice a day
for five days. Bexovid is available by prescription only and should be
initiated as soon as possible after diagnosis of COVID-19 and within five days
of symptom onset.

 

Mr. Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, commented:
"Having previously introduced the world's first generic COVID-19 treatments of
remdesivir and molnupiravir, we are pleased to add this breakthrough therapy
to our portfolio. It is further testament to our commitment to making
affordable treatments accessible as soon as possible. As data continues to
emerge demonstrating the effectiveness of nirmatrelvir and ritonavir against
the the fast-emerging Omicron variant, we believe that Bexovid has the
potential to be a powerful tool in combating the ongoing pandemic."

 

 

For further information please visit www.beximcopharma.com
(http://www.beximcopharma.com) or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, ext. 20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Vadim Alexandre / Abigail Wayne

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 5,500 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the world.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCWPGQWPUPGGUU